Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07131007) titled 'Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics' on Aug. 11.
Study Type: Observational [Patient Registry]
Primary Sponsor: Hebei Medical University Fourth Hospital
Condition:
Organ Function Damage in Immune - Related Adverse Events (irAEs) Associated With Immune Checkpoint Inhibitors (ICIs) During Tumor Immunotherapy
Intervention:
Behavioral: Immunotherapy Monitoring and Sample Collection
Recruitment Status: Not recruiting
Date of First Enrollment: August 13, 2025
Target Sample Size: 2000
To know more, visit https://clinicaltrials.gov/ct2/show/N...